Q-omics provides the consensus-scored RPL34P23 profile across patient tissues and cancer cell-line models. RPL34P23 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL34P23 is differentially expressed in 3, with the highest sampling consensus in PRAD. Additionally, RPL34P23 RNA expression shows 5,983 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, PRAD, and STAD as cancer lineages where RPL34P23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL34P23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL34P23 survival associations across molecular data types. RPL34P23 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL34P23 RNA expression–survival associations across cancer types. High RPL34P23 expression shows unfavorable associations in KIRC, KICH, CESC and LUSC, but favorable associations in OV and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL34P23 RNA expression.
This table summarizes RPL34P23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL34P23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL34P23 shows higher tumor expression in PRAD, LIHC and COAD. The PRAD box plot shows higher RPL34P23 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p = .044).
This table shows molecular features associated with RPL34P23 in patient tissues and cancer cell lines. In patient samples, RPL34P23 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
